- Home
- EPAM vs ROIV Comparison
EPAM vs ROIV Comparison
Compare EPAM & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- ROIV
- Stock Information
- Founded
- EPAM 1993
- ROIV 2014
- Country
- EPAM United States
- ROIV United Kingdom
- Employees
- EPAM N/A
- ROIV N/A
- Industry
- EPAM EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- EPAM Technology
- ROIV Health Care
- Exchange
- EPAM Nasdaq
- ROIV Nasdaq
- Market Cap
- EPAM 8.2B
- ROIV 7.8B
- IPO Year
- EPAM 2012
- ROIV N/A
- Fundamental
- Price
- EPAM $182.83
- ROIV $10.99
- Analyst Decision
- EPAM Buy
- ROIV Buy
- Analyst Count
- EPAM 14
- ROIV 4
- Target Price
- EPAM $231.43
- ROIV $17.50
- AVG Volume (30 Days)
- EPAM 631.0K
- ROIV 7.3M
- Earning Date
- EPAM 08-07-2025
- ROIV 08-07-2025
- Dividend Yield
- EPAM N/A
- ROIV N/A
- EPS Growth
- EPAM N/A
- ROIV N/A
- EPS
- EPAM 7.15
- ROIV N/A
- Revenue
- EPAM $4,864,167,000.00
- ROIV $29,053,000.00
- Revenue This Year
- EPAM $15.44
- ROIV $2.64
- Revenue Next Year
- EPAM $7.38
- ROIV $378.09
- P/E Ratio
- EPAM $25.56
- ROIV N/A
- Revenue Growth
- EPAM 4.72
- ROIV N/A
- 52 Week Low
- EPAM $138.15
- ROIV $8.73
- 52 Week High
- EPAM $269.00
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- EPAM 62.87
- ROIV 44.75
- Support Level
- EPAM $158.54
- ROIV $10.83
- Resistance Level
- EPAM $183.04
- ROIV $11.82
- Average True Range (ATR)
- EPAM 4.35
- ROIV 0.32
- MACD
- EPAM 1.16
- ROIV -0.07
- Stochastic Oscillator
- EPAM 98.58
- ROIV 16.24
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.